Comparison of Efficacy and Adherence of Patient-Preferred (1 Unit Daily) and ADA/EASD Guideline-Recommended (2 Units Every 3 Days) Basal Insulin Titration Algorithms: Multicenter, Randomized, Clinical Study
Ling Li,Xiaodan Zhang,Tong Zhang,Liankun Zeng,Mingrun Lin,Yanli Li,Wangen Li
DOI: https://doi.org/10.2147/ppa.s446855
2024-03-18
Patient Preference and Adherence
Abstract:Ling Li, 1 Xiaodan Zhang, 1 Tong Zhang, 2 Liankun Zeng, 3 Mingrun Lin, 4 Yanli Li, 4 Wangen Li 1 1 Department of Endocrinology, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, People's Republic of China; 2 Department of Endocrinology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, People's Republic of China; 3 Department of Endocrinology, The Fourth Affiliated Hospital, Guangzhou Medical University, Guangzhou, People's Republic of China; 4 Department of Endocrinology, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, People's Republic of China Correspondence: Wangen Li; Yanli Li, Email ; Aim: Insulin titration often faces inertia, hindering glycemic control. A patient-centered approach empowers patients to overcome this inertia. This study aims to compare the effectiveness of patient-preferred and guideline-recommended self-titration algorithms in achieving glycemic targets and improving adherence. Methods: Outpatients with type 2 diabetes (T2D) who did not respond to oral antihyperglycemic drugs (OAD) were assessed. They were randomly assigned to patient-preferred and guideline-recommended groups. In the patient-preferred group, individuals selected an algorithm to self-adjust their insulin glargine dosage by 2 units every 3 days if the mean fasting blood glucose (FBG) over the past 3 consecutive days was ≥ 7.0 mmol/L, or by 1 unit daily if the FBG on the same day was ≥ 7.0 mmol/L. In the guideline-recommended group, insulin glargine was titrated by 2 units every 3 days if the mean FBG over the past 3 consecutive days was ≥ 7.0 mmol/L. The FBG target was set below < 7.0 mmol/L. Results: Thirty-nine participants in the patient-preferred group and 42 in the guideline-recommended group completed the study. The cumulative rates of achieving the FBG target in the patient-preferred group compared to the guideline-recommended group were 69.2% vs 54.8% ( χ 2=1.792, p=0.181) in week 1, 89.7% vs 73.8% ( χ 2=3.403, p = 0.065) in week 2, 94.9% vs 76.2% ( χ 2=17.638, p=0.000) in week 3, and 100.0% vs 88.1% ( χ 2=4.405, p=0.036) in week 4. Adherence rates were significantly higher in the patient-preferred group (97.4%, 37/38) compared to the guideline-recommended group (66.7%, 28/42) ( χ 2=12.688, p=0.000). Insulin glargine dosage at FBG target achievement was 21.2± 4.3 U in the patient-preferred group and 18.8± 6.7 U in the guideline-recommended group (t=1.888, p=0.063). Hypoglycemia was reported in 1 patient in the guideline-recommended group, with no instances in the patient-preferred group. Conclusion: The patient-preferred self-titration algorithm demonstrates a higher rate of reaching glucose targets and improved adherence. Trial Registration Number: ChiCTR2100050805. Keywords: type 2 diabetes, glargine, self-titration, adherence, preference Type 2 diabetes (T2D) is a progressive condition, necessitating insulin therapy to achieve glucose targets for many patients, despite the array of available antidiabetic treatments. 1 Basal insulin, when added to metformin and other oral agents, serves as a convenient initial regimen. 1 Once instituted, titration becomes pivotal for attaining desired glucose levels. 2 The evolution of insulin titration can be categorized into two phases. Prior to the 1980s, physicians predominantly handled insulin titration for most patients. However, initiating insulin often required frequent contact with healthcare providers, which proved challenging due to resource constraints. 3 Notably, reports such as UKPDS 33 and 34 indicated insulin dose adjustments only every three months. 4,5 The 1990s ushered in the era of self-titration of insulin through self-monitoring of blood glucose (SMBG), enhancing the maintenance of glycemic control. 6,7 The introduction of long-acting insulins, safer than NPH insulin, prompted numerous randomized controlled trials involving glargine and detemir, which demonstrated non-inferiority or superiority of patient-titrated insulin algorithms compared to standard care for glycemic control in T2D. 8–12 The 2018 ADA Standards of Medical Care in Diabetes recommended insulin self-titration, suggesting 2–4 units once or twice weekly. 13 Trials such as ATLAS, AT.LANTUS, and ATAS employed insulin self-titration algorithms entailing increments of 2 or 4 units of glargine every three days. 8–10 Subsequently, starting in 2019, both ADA, EASD consensus, and AACE recommended titrating basal insulin by 2 units every three days. 14,15 Interestingly, our prior -Abstract Truncated-
medicine, general & internal